Dova Pharmaceuticals (NASDAQ:DOVA) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday.

Several other brokerages also recently issued reports on DOVA. Leerink Swann upgraded shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price target on the stock in a research report on Tuesday, September 26th. Jefferies Group boosted their price objective on Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, Zacks Investment Research cut Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $32.75.

Shares of Dova Pharmaceuticals (NASDAQ DOVA) traded up $2.20 during midday trading on Friday, reaching $28.55. 92,875 shares of the company traded hands, compared to its average volume of 93,891. The firm has a market cap of $793.52 and a P/E ratio of -32.08. Dova Pharmaceuticals has a 1-year low of $16.98 and a 1-year high of $32.75.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). During the same period last year, the business posted ($0.41) EPS. analysts predict that Dova Pharmaceuticals will post -1.51 EPS for the current year.

A number of large investors have recently made changes to their positions in DOVA. California State Teachers Retirement System bought a new stake in Dova Pharmaceuticals during the 3rd quarter worth about $202,000. Laurion Capital Management LP bought a new stake in Dova Pharmaceuticals during the 2nd quarter worth about $223,000. Schwab Charles Investment Management Inc. bought a new stake in Dova Pharmaceuticals during the 3rd quarter worth about $241,000. Bank of New York Mellon Corp bought a new stake in Dova Pharmaceuticals during the 3rd quarter worth about $340,000. Finally, JPMorgan Chase & Co. bought a new stake in Dova Pharmaceuticals during the 2nd quarter worth about $382,000. 26.20% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/06/bidaskclub-lowers-dova-pharmaceuticals-dova-to-sell.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.